Literature DB >> 6357067

Multiple-dose pharmacokinetics of ceftazidime in cancer patients.

I Garcia, V Fainstein, R G Smith, G P Bodey.   

Abstract

The pharmacokinetic parameters of ceftazidime were determined in 25 patients with neoplastic diseases. A group of 13 patients each received 1 g of ceftazidime over 15 min as a single intravenous dose. The mean peak drug concentration in serum was 77.4 micrograms/ml, and the serum half-life was 144 min. Urinary excretion at 12 h was 64.5%. These 13 patients also received 2 g of ceftazidime over 15 min at 8-h intervals for 7 or 8 days. The mean peak drug concentrations in serum were 103.6 micrograms/ml on day 1 and 87 micrograms/ml on day 7 or 8. A second group of 12 patients received 1 g of ceftazidime over 30 min, followed by 1 g over 2 h and every 4 h thereafter. The mean peak drug concentration in serum at 30 min was 57.5 micrograms/ml. Average peak and trough levels obtained on day 2 or 3 were 65 and 34.8 micrograms/ml, respectively, and remained in this range thereafter. The above-mentioned dose schedules produced high and adequate ceftazidime concentrations in serum.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6357067      PMCID: PMC185126          DOI: 10.1128/AAC.24.2.141

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Pharmacokinetics of cephalosporin antibiotics.

Authors:  J M Brogard; F Comte; M Pinget
Journal:  Antibiot Chemother (1971)       Date:  1978

2.  Pharmacokinetics of cefotaxime.

Authors:  K P Fu; P Aswapokee; I Ho; C Matthijssen; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

3.  The combination of pivmecillinam and pivampicillin in the treatment of acute enteric fever.

Authors:  D Tanphaichitra; A Bussayanond; O Christensen
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

4.  In-vitro antibacterial activity of cefoperazone, a piperazine cephalosporin.

Authors:  A King; C Warren; K Shannon; I Phillips
Journal:  J Antimicrob Chemother       Date:  1981-08       Impact factor: 5.790

5.  Antibiotics and travellers' diarrhoea.

Authors:  A M Geddes
Journal:  J Antimicrob Chemother       Date:  1981-10       Impact factor: 5.790

6.  The role of schedule of antibiotic therapy on the neutropenic patient.

Authors:  G P Bodey; M Valdivieso; B S Yap
Journal:  Infection       Date:  1980       Impact factor: 3.553

7.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

8.  Comparative in vitro study in new cephalosporins.

Authors:  G P Bodey; V Fainstein; A M Hinkle
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

9.  Clinical pharmacology of moxalactam in patients with malignant disease.

Authors:  E H Estey; S S Weaver; D H Ho; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

  9 in total
  4 in total

1.  Population pharmacokinetics of continuous infusion ceftazidime.

Authors:  B C Frame; B F Facca; D P Nicolau; S N Triesenberg
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

Review 2.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

Review 3.  Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations.

Authors:  M LeBel; M Spino
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.